LANOXIN TABLET
Země: Kanada
Jazyk: angličtina
Zdroj: Health Canada
Charakteristika produktu
(SPC)
07-01-2016
Některé dokumenty pro tento produkt momentálně nejsou k dispozici, můžete poslat požadavek našemu zákaznickému servisu a my vás upozorníme, jakmile je dokážeme získat.
Poslat žádost.
Poslat žádost.
Aktivní složka:
DIGOXIN
Dostupné s:
PHARMASCIENCE INC
ATC kód:
C01AA05
INN (Mezinárodní Name):
DIGOXIN
Dávkování:
0.0625MG
Léková forma:
TABLET
Složení:
DIGOXIN 0.0625MG
Podání:
ORAL
Jednotky v balení:
250
Druh předpisu:
Prescription
Terapeutické oblasti:
CARDIOTONIC AGENTS
Přehled produktů:
Active ingredient group (AIG) number: 0107281004; AHFS:
Stav Autorizace:
CANCELLED POST MARKET
Datum autorizace:
2016-11-24
Charakteristika produktu
PRODUCT MONOGRAPH
PR
LANOXIN
®
Digoxin Tablets, C.S.D.
0.0625 mg, 0.125 mg and 0.25 mg
CARDIOTONIC GLYCOSIDE
PHARMASCIENCE INC. DATE OF REVISION:
6111 Royalmount Ave., Suite 100 January 6, 2016
Montreal, Quebec
H4P 2T4
www.pharmascience.com
Control No. 188181
®
Registered trademark of Pharmascience Inc.
MPORTANT: PLEASE READ
_ _
_LANOXIN Product Monograph _
_Page 2 of 38_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................... 3
SUMMARY
PRODUCT
INFORMATION
.................................................................................
3
INDICATIONS
AND
CLINICAL
USE
......................................................................................
3
CONTRAINDICATIONS
...........................................................................................................
4
WARNINGS
AND
PRECAUTIONS
..........................................................................................
4
ADVERSE
REACTIONS
............................................................................................................
8
DRUG
INTERACTIONS
..........................................................................................................
11
DOSAGE
AND
ADMINISTRATION
......................................................................................
18
OVERDOSAGE
........................................................................................................................
22
ACTION
AND
CLINICAL
PHARMACOLOGY
.....................................................................
23
STORAGE
AND
STABILITY
..................................................................................................
28
DOSAGE
FORMS,
COMPOSITION
AND
PACKAGING ...................................................... 28
PART II: SCIENTIFIC INFORMATION
................................................................................
29
PHARMACEUTICAL
INFORMATION
..................................................................................
29
CLINICAL
TR
Přečtěte si celý dokument
